Business
Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
First Patient Dosed in Phase 1 trial of Briquilimab in Lower-Risk Myelodysplastic SyndromeStrengthened the Board of Directors and Management Team with
About this update from Jasper Therapeutics, Inc.
[{"type":"text","content":"First Patient Dosed in Phase 1 trial of Briquilimab in Lower-Risk Myelodysplastic SyndromeStrengthened the Board of Directors and Management Team with Multiple Appointments REDWOOD CITY, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced results for the fiscal quarter ended June 30, 2023, and provided a business update. “During our second quarter, we continued our preparations to begin a study in chronic spontaneous urticaria, which we anticipate initiating in the coming months,” said Ronald Martell, President and Chief Executive Officer of Jasper. “We also dosed the first patient in our Phase 1 trial evaluating briquilimab as second-line therapy in subjects with LR-MDS, and took significant additional steps taken to strengthen our Board and leadership teams. With a strong balance sheet, enhanced organization and a sound development plan, we believe we are well-positioned to advance our priority briquilimab development programs in rare and chronic diseases driven by mast and stem cells.” Highlights for Q2 2023 and Recent Weeks Dosed first patients in a Phase 1 trial of briquilimab in LR-MDS The open-label, single-arm Phase 1 trial will evaluate the safety and tolerability of briquilimab as a second-line therapy in subjects with LR-MDS. The trial will employ a 3+3 dose escalation design to identify the maximum tolerated dose or optimal biologic dose and recommended Phase 2 dose of briquilimab monotherapy as a chronic therapeutic for LR-MDS patients with documented cytopenia, such as red blood cell transfusion dependence, thrombocytopenia or neutropenia.The trial is being conducted at Moffitt Cancer Center in Tampa, FL, and is expected to enroll up to 30 patients that will receive briquilimab every 56 days for 4 consecutive cycles. Key Appointments Scott Brun, M.D. appointed to the Board of DirectorsStephen J. Galli, M.D. appointed to Scientific Advisory BoardDaniel Adelman, M.D. appointed to Scientific Advisory BoardEdwin J. Tucker, M.D. appointed as Chief Medical OfficerPatricia Carlo...